One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Improving Outcomes for Patients With Epidermal Necrolysis
Robert G. Micheletti, MD; Megan H. Noe, MD, MPH, MSCE
doi : 10.1001/jamadermatol.2020.3655
JAMA Dermatol. 2020;156(12):1289-1290
Underestimation of Cutaneous Squamous Cell Carcinoma Incidence, Even in Cancer Registries
Mackenzie R. Wehner, MD, MPhil
doi : 10.1001/jamadermatol.2020.3678
JAMA Dermatol. 2020;156(12):1290-1291
Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis
Hui Kai Koh, MBBS; Stephanie Fook-Chong; Haur Yueh Lee, MBBS, MRCP (UK), MMed (Int Med)
doi : 10.1001/jamadermatol.2020.3654
JAMA Dermatol. 2020;156(12):1294-1299
Importance Epidermal necrolysis is a rare severe cutaneous drug reaction associated with high mortality. The ABCD-10 score (age, bicarbonate, cancer, dialysis, 10% body surface area), a new prognostic score for mortality in epidermal necrolysis, was recently developed and validated in the US. However, to our knowledge, it remains to be externally validated in other cohorts.
Incidence of Multiple vs First Cutaneous Squamous Cell Carcinoma on a Nationwide Scale and Estimation of Future Incidences of Cutaneous Squamous Cell Carcinoma
Selin Tokez, MSc; Loes Hollestein, PhD; Marieke Louwman, PhD; et al.
doi : 10.1001/jamadermatol.2020.3677
JAMA Dermatol. 2020;156(12):1300-1306
Importance Until now, most studies on cutaneous squamous cell carcinoma (cSCC) incidence rates concerned only the first cSCC per patient. Given the increase in incidence rates and the frequent occurrence of subsequent cSCCs per patient, population-based data on the incidence rates of both first and multiple cSCCs are needed.
Sebaceous Carcinoma Incidence and Survival Among Solid Organ Transplant Recipients in the United States, 1987-2017
Michael R. Sargen, MD; Elizabeth K. Cahoon, PhD; Charles F. Lynch, MD, PhD; et al.
doi : 10.1001/jamadermatol.2020.3111
JAMA Dermatol. 2020;156(12):1307-1314
Importance Risk of sebaceous carcinoma (SC), a rare skin cancer associated with Muir-Torre syndrome, is elevated among solid organ transplant recipients (SOTRs). However, population studies evaluating this association and assessing survival for posttransplant cases are lacking, and further understanding of SC epidemiology in this immunosuppressed population could provide etiologic and clinical insights.
Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum ContagiosumTwo Phase 3 Randomized Clinical Trials
Lawrence F. Eichenfield, MD; Wendy McFalda, MD; Bradford Brabec, MD; et al.
doi : 10.1001/jamadermatol.2020.3238
JAMA Dermatol. 2020;156(12):1315-1323
Importance Molluscum contagiosum (MC) is a common viral skin infection that primarily affects children. Cantharidin, a topical vesicant, has a long history of use for MC in compounded formulations, but the safety and efficacy of doses, regimens, and application methods have not been demonstrated in large-scale trials.
Assessment of Incidence Rate and Risk Factors for Keratoacanthoma Among Residents of Queensland, Australia
Magdalena Claeson, MD, PhD; Nirmala Pandeya, MMedSc, PhD; Jean-Claude Dusingize, MD, PhD; et al.
doi : 10.1001/jamadermatol.2020.4097
JAMA Dermatol. 2020;156(12):1324-1332
Importance Keratoacanthoma (KA) is a common and generally benign keratinocyte skin tumor. Reports of the incidence rates of KA are scant. In addition, the risk factors for KA are not well understood, although associations with UV radiation exposure and older age have been described.
Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic DermatitisA Randomized Clinical Trial
Kristian Reich, MD; Kenji Kabashima, MD; Ketty Peris, MD; et al.
doi : 10.1001/jamadermatol.2020.3260
JAMA Dermatol. 2020;156(12):1333-1343
Importance Baricitinib, an oral selective Janus kinase 1 and 2 inhibitor, effectively reduced disease severity in moderate to severe atopic dermatitis (AD) in 2 phase 3 monotherapy studies.
Effect of Risankizumab on Patient-Reported Outcomes in Moderate to Severe PsoriasisThe UltIMMa-1 and UltIMMa-2 Randomized Clinical Trials
Matthias Augustin, MD; Jo Lambert, MD, PhD; Carla Zema, PhD; et al.
doi : 10.1001/jamadermatol.2020.3617
JAMA Dermatol. 2020;156(12):1344-1353
Importance Demonstrating the value of therapies from a patient’s perspective is increasingly important for patient-centered care.
Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo NodularisA Secondary Analysis of a Randomized Clinical Trial
Miriam Kimel, PhD; Claudia Zeidler, MD; Paul Kwon, MD; et al.
doi : 10.1001/jamadermatol.2020.3071
JAMA Dermatol. 2020;156(12):1354-1358
Importance There is an unmet need for psychometrically sound instruments to measure pruritus associated with prurigo nodularis (PN).
Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort
Kelsey R. van Straalen, MD; Errol P. Prens, MD, PhD; Gonneke Willemsen, PhD; et al.
doi : 10.1001/jamadermatol.2020.3630
JAMA Dermatol. 2020;156(12):1359-1362
Importance Hidradenitis suppurativa is a chronic, inflammatory skin disease in which genetic factors are considered to play a role, with up to 38% of patients reporting a family history. Variations in the ?-secretase genes are found mainly in familial cases with an autosomal dominant pattern of inheritance. These variations are rare in the general population with hidradenitis suppurativa, even in patients who report a family history of the disease.
Papuloerythroderma of Ofuji
Sizhe Li, MD; Xiaoling Yu, MD; Tao Wang, MD
doi : 10.1001/jamadermatol.2020.2973
JAMA Dermatol. 2020;156(12):1365
Ventriculoperitoneal Shunt Infection
Cristina L?pez-S?nchez, MD; Eduardo Rozas-Mu?oz, MD; Juan Francisco Mir-Bonafé, MD
doi : 10.1001/jamadermatol.2020.2990
JAMA Dermatol. 2020;156(12):1366
A Solitary Lump on the Scalp
Lucas Samuel Perinazzo Pauvels, MD; Beatriz da Silva Souza, MD; Juliano Peruzzo, MD, MSc
doi : 10.1001/jamadermatol.2020.3577
JAMA Dermatol. 2020;156(12):1367-1368
Generalized Pruriginous Eruption on a Patient With Leukemia
Luc?a N??ez-Hip?lito, MD; Cristina Moya-Mart?nez, MD; Luis Requena, MD
doi : 10.1001/jamadermatol.2020.3999
JAMA Dermatol. 2020;156(12):1369-1370
Characterizing Disease Features and Other Medical Diagnoses in Patients With Pityriasis Rubra Pilaris
Katherine Halper, BA; Benjamin Wright, BS; Nolan J. Maloney, MD; et al.
doi : 10.1001/jamadermatol.2020.3426
JAMA Dermatol. 2020;156(12):1373-1374
Prevalence of Dermatitis Herpetiformis Within the iCureCeliac Patient-Powered Research Network—Patient Characteristics and Dietary Counseling
Bridget E. Shields, MD; Joel M. Gelfand, MD, MSCE; Lynne Allen-Taylor, PhD; et al.
doi : 10.1001/jamadermatol.2020.3431
JAMA Dermatol. 2020;156(12):1374-1376
Early Features of Progressive Hemifacial Atrophy—Clinical and Imaging Findings
Krystal M. Jones, MD; Jennifer K. Tan, MD; Ahmad I. Alomari, MD, MSc; et al.
doi : 10.1001/jamadermatol.2020.2593
JAMA Dermatol. 2020;156(12):1376-1379
TEMPI Syndrome With Progressive Telangiectasias Associated With Pulmonary Deterioration
Michael Lor, BA; Michelle Cheng, MD; Brannen Liang, MD; et al.
doi : 10.1001/jamadermatol.2020.2668
JAMA Dermatol. 2020;156(12):1379-1380
Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy
Dustin H. Marks, MD; Matthew D. Mansh, MD
doi : 10.1001/jamadermatol.2020.4380
JAMA Dermatol. 2020;156(12):1380-1381
Potential Role for Topical Antiandrogens in the Management of Acne Among Patients Receiving Masculinizing Hormone Therapy—Reply
Diane Thiboutot, MD; Martina Cartwright, PhD; Alessandro Mazzetti, MD
doi : 10.1001/jamadermatol.2020.3341
JAMA Dermatol. 2020;156(12):1381
Cellulitis
Jane Han, BS; Adam Faletsky, BS; Arash Mostaghimi, MD
doi : 10.1001/jamadermatol.2020.2083
JAMA Dermatol. 2020;156(12):1384
